Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Miracor Medical Systems

Request full access

Cardiac therapy improving myocardial microcirculatory function

Awans, BelgiumFounded 2008Biotech & Life Sciences

About Miracor Medical Systems

Miracor Medical is a Belgian medical device company founded in 2008 by Professor Dr. Dr. Werner Mohl, Earlybird, and Delta Partners. The company develops and commercializes the PiCSO (Pressure-controlled intermittent Coronary Sinus Occlusion) Impulse System, a therapeutic device for patients with impaired cardiac function. The current CEO is Olivier Delporte.

The company's core product, the PiCSO Impulse System, is designed as an adjunctive therapy used during Percutaneous Coronary Intervention (PCI) for patients suffering from acute myocardial infarction (heart attack). The system consists of a driving console and a catheter with a balloon that is positioned in the coronary sinus. It works by intermittently occluding the coronary sinus, which increases pressure and redistributes blood flow to damaged areas of the heart muscle, aiming to clear microvascular obstruction and reduce the size of the infarct (damaged tissue). A reduction in infarct size is strongly associated with a lower risk of heart failure and mortality.

Miracor operates in the cardiovascular medical device market, targeting interventional cardiologists as its primary clients. Its business model centers on the sale of the PiCSO console and the associated single-use catheters. The company has achieved significant milestones, including receiving a CE Mark for the PiCSO Impulse System in June 2020, allowing for commercialization in Europe, and gaining 'Breakthrough Device Designation' from the U.S. Food and Drug Administration (FDA) in 2019. The company has been actively conducting clinical trials across Europe to gather further evidence of the therapy's benefits and received FDA IDE approval for a pivotal study in the US in 2022.

Since its founding, Miracor Medical has raised approximately $117 million in funding over eight rounds from a mix of venture capital firms and public investors, including Ming Capital, BioMedPartners, Peppermint Venture Partners, and Yong hua. The company was initially based in Vienna, Austria, before relocating its headquarters to Awans, Belgium, in 2018 to support its growth and development phase.

Source: Dealroom company data

At a glance

Status
Operational
Employees
7
Open positions
None listed
Dealroom signal
29.0/100
Industry
Health
Sub-industry
BioTechnology, Medical Devices
Sector
Biotechnology, Cardiology and cardiovascular, Patient Care, Sustainable Development Goals, Hard Tech, Horizon Europe, DT and LS, science-based
Technology
Deep Tech
Business model
Manufacturing
Client focus
B2C

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES EOther financing Sep 2020 $26M $106M Earlybird Venture Capital · Quest for Growth · Noshaq · SFPIM —
SERIES DOther financing Sep 2018 $5.5M $22M Quest for Growth · Noshaq · SFPIM · Ming Capital —
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Growth signals

Miracor Medical Systems website traffic

Latest recorded traffic for Miracor Medical Systems is 2.1K monthly website visits, up 40% over the last three months. Miracor Medical Systems's team grew 0% over the past year.

Latest monthly visits2.1K 3-month web change+40% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Miracor Medical Systems in the Awans ecosystem

Live from Dealroom

The Miracor Medical Systems office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

15 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed2 investors entered at this stage

  • Austrian Research Promotion Agency (FFG)
  • MedTech Innovator

Series A6 investors entered at this stage

Series B and later7 investors entered at this stage

  • Peppermint Venture Partners
  • Ming Capital
  • Noshaq
  • Wallonie Entreprendre
  • SFPIM
  • Quest for Growth
  • Yonghua Capital
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 3 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇩🇪 Germany50%
🇧🇪 Belgium50%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Miracor Medical Systems on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Miracor Medical Systems’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.